Relmada Therapeutics (RLMD) Q3 2026 earnings review
Relmada's bladder drug holds responses, but factory deadlines remain open
Relmada Therapeutics, a clinical-stage developer of bladder cancer and brain disorder drugs, reported encouraging 18-month cancer remission data while keeping its year-end regulatory deadlines. Among patients whose bladder tumors were gone at one year, 86% stayed cancer-free at 18 months. Operating cash burn rose to $12.6 million as research spending more than doubled and administrative overhead fell, leaving $202 million in cash. Chief executive Sergio Traversa outlined a supply plan for late-stage trials and maintained the cash outlook through 2029.
| Cash and short-term investments | $202.1M funds operations through 2029 |
|---|---|
| Operating cash burn | $12.6M $9.6M last quarter |
| NDV-01 18-month remission rate | 86% 12 of 14 evaluable 12-month responders |
| US regulatory filings (NDV-01 & sepranolone) | Unchanged planned by year-end 2026 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because the main hurdle — filing for permission to start US human trials by year-end after four delays — remains open until December. The 18-month bladder cancer data and lower administrative costs helped, but the one-year remission rate in the key patient group dipped to 73% as more patients reached the mark, and two others saw their cancer worsen at 15 months.
The question now is whether factory work is truly finished so the US regulatory filings happen before December 31. Either the contract manufacturer has already made the clinical batches and is simply finishing stability paperwork, or unresolved factory hurdles will force a fifth delay into 2027. A year-end regulatory filing announcement will settle it within seven weeks.
🐂 Bull Case
Early Bladder Cancer Data Hold Up
Relmada is developing NDV-01, a chemotherapy gel placed directly into the bladder to treat non-muscle invasive bladder cancer (NMIBC), where tumors have not yet grown into the muscle wall. Chief business officer Bipin Dalmia said the first 18-month results from its Phase 2 study show "extended durability of complete response and continued favorable tolerability". One quarter after saying it had not looked past 12 months, the company published the 18-month follow-up.
- 18-month cancer-free rate among 12-month responders: 86% (12 of 14 patients)
- 18-month cancer-free rate in the hardest-to-treat group: 88% (7 of 8 patients)
- Severe treatment-related side effects or dropouts: 0% across 51 patients
This matters because bladder tumors return in 50% to 80% of patients within five years, so regulators care about how long a drug keeps cancer away. Keeping 7 of 8 patients in remission at 18 months after standard Bacillus Calmette-Guérin (BCG) immunotherapy failed gives the company a stronger case as it prepares for late-stage trials.
What to watch: the 18-month remission rate once all 23 patients in the extension study reach that mark in early 2027. Holding above 75% across the full group would strengthen the single-arm regulatory filing.
Spending Shifts From Overhead to Lab Work
During the first half of the year, administrative overhead and executive pay consumed more of Relmada's budget than medical research. In the third quarter, the biotechnology company flipped that ratio as it prepared its two drug candidates for human trials.
Research and development spending more than doubled from a year ago to $9.2 million, or 70.4% of total operating expenses, up from 39.1% a year earlier, by our math. General and administrative costs fell 38.3% from a year ago to $3.9 million because expenses for stock appreciation rights — cash bonuses tied to the stock — and stock grants dropped. Spending money on drug supply and trial sites rather than overhead puts more of the cash pile to work on clinical data.
What to watch: general and administrative spending in the fourth quarter. Keeping overhead near $4 million a quarter would show that cash-settled bonus expenses are staying under control.
Cash Pile Covers Three Years of Trials
Relmada ended September with $202.1 million in cash and short-term investments, down from $217.7 million in June. It burned $12.6 million in operating cash during the quarter, up from $9.6 million in the second quarter as drug manufacturing and trial preparation ramped up.
The company reiterated that its cash will fund operations through 2029, including completing both late-stage registration trials for NDV-01, while pending patent applications could protect the drug until 2047. By our math, the 2029 target allows average cash burn to rise to about $15.5 million a quarter over the next 13 quarters, giving the clinical team enough room to pay for patient enrollment without raising more money.
What to watch: quarterly operating cash burn once the two Phase 3 cohorts begin enrolling patients in early 2027. A quarterly burn rate staying near $15.5 million would confirm the cash pile can last through the end of 2029.
🐻 Bear Case
A Plan on Paper Is Not Drug
Chief executive Sergio Traversa said "we have established a manufacturing plan to provide uninterrupted clinical supply through the completion of the Phase 3 SPECTRUM program". After four timeline delays over the past seven quarters, getting factory batches made and tested for shelf stability is the single hurdle blocking late-stage trials.
Despite the upbeat language, the release did not confirm that its contract manufacturer has actually produced the clinical batches or placed them on stability testing. Having a plan for future trial supply is not the same as having finished batches data in hand for the US Food and Drug Administration (FDA). With less than seven weeks left in the year, any hiccup in batch testing would push the regulatory filing into 2027.
What to watch: the official announcement that Relmada has submitted the Investigational New Drug (IND) application — the request for FDA permission to start human trials — by December 31, 2026. Missing that year-end deadline would mark a fifth delay for the program.
Bigger Sample Trims Cure Rate
Relmada's bladder cancer gel relies on a single-hospital Phase 2 trial outside the US to prove its worth before larger studies begin. As more patients reached the one-year mark this quarter, the numbers softened slightly from earlier cuts.
In the BCG-unresponsive group — patients whose tumors did not respond to standard immunotherapy — the 12-month complete response rate dipped to 73% (11 of 15 patients), down from 80% (8 of 10 patients) in the prior quarter. In addition, two patients who had never received BCG saw their cancer worsen into muscle-invasive disease at the 15-month checkup, ending the trial's 100% progression-free record past one year. Small sample sizes swing easily, so a larger multi-hospital Phase 3 trial may see lower remission rates.
What to watch: the 12-month complete response rate once all 23 BCG-unresponsive patients in Cohort 1 reach the one-year mark. A further drop toward 60% would narrow the drug's lead over approved rivals.
Risks This Quarter Didn't Answer
Three standing risks around rival bladder cancer drugs, regulatory standards, and the second pipeline drug got no new answers this quarter.
- Crowded bladder cancer market: four drugs are already approved for first-line BCG-unresponsive patients, and generic chemotherapy mixes are widely used; Phase 3 enrollment speed in 2027 will test doctor demand.
- Undefined FDA approval bar: regulators have not set a minimum remission rate or duration for the single-arm second-line trial; only the final FDA review will settle whether the data are strong enough.
- Sepranolone syringe testing: Relmada is still "finalizing the stability testing of the pre-filled syringe (PFS) delivery system" for its brain-disorder drug; a year-end 2026 regulatory filing will show if the device passed.
👓 Other Themes
Phase 3 Renamed as Sizing Reviewed
Relmada renamed its planned Phase 3 bladder cancer program from RESCUE to SPECTRUM to "reflect the potential breadth of NDV-01 across the NMIBC disease spectrum", Dalmia said. The company kept its two registration pathways, plus a 50-patient exploratory group. However, the corporate presentation now marks the 276-patient sample size for the intermediate-risk trial as "under review", suggesting potential adjustments to the trial's size before enrollment starts.
💲 Other KPIs
Weighted average shares more than tripled, rising 238.8% from 33.2 million a year ago after the November 2025 stock offering and March 2026 private placement. Because the company spread its losses over more shares, net loss per share shrank from $0.30 to $0.12 even though the dollar loss grew.
The balance-sheet liability for stock appreciation rights — employee bonuses that pay out in cash when the stock rises — fell 25.5% from $5.08 million last quarter, by our math, though it remains up from $1.06 million at year-end 2025. The drop reduced third-quarter administrative expenses and eased immediate pressure on cash.
Quarterly net loss widened 37.4% from $10.1 million a year ago, and rose from $12.9 million in the second quarter. Higher research and development spending drove the operating loss, while $3.0 million in realized and unrealized losses on short-term investments outweighed $2.3 million in interest income.
🔮 Guidance
Unchanged. Relmada expects its $202.1 million in cash and short-term investments to fund operations through the end of 2029, including completing both registration cohorts of the Phase 3 SPECTRUM bladder cancer program. By our math, that leaves room for up to $15.5 million in average quarterly cash burn over the next 13 quarters, compared with $12.6 million burned this quarter.
Unchanged. The biotechnology group still plans to submit its US regulatory application to begin human trials of NDV-01 by the end of 2026, with the Phase 3 SPECTRUM trials starting once the FDA clears the filing. Management has re-dated this start four times over the past seven quarters, moving the target from late 2025 to mid-2026 and then to year-end 2026.
Unchanged. The company plans to submit its US regulatory application for sepranolone by year-end 2026 and start a Phase 2b trial in Prader-Willi syndrome — a rare genetic disorder causing behavioral and metabolic problems — upon clearance. Finalizing stability tests on the pre-filled syringe remains the gating step after previous timeline delays from late 2025 and mid-2026.
❓ Key Questions
Have the clinical NDV-01 batches been manufactured and placed on stability?
The release highlights a manufacturing plan for Phase 3 supply, but does not state whether the initial batches needed for the year-end 2026 regulatory filing have finished production and entered stability testing.
Why is the intermediate-risk Phase 3 sample size under review?
Slide 3 and Slide 21 of the corporate presentation mark the 276-patient sample size for Cohort IRA as 'under review'. A larger target would increase trial costs and lengthen the 15-to-18-month enrollment timeline.
What drove the two cancer progressions at Month 15?
Two BCG-naive patients with T1 tumors saw their cancer progress to muscle-invasive disease at 15 months. Knowing whether these patients missed maintenance doses or had aggressive tumor features matters for positioning the drug in earlier treatment lines.
When will Relmada share its first Phase 3 interim data?
After dropping its earlier goal of reporting three-month Phase 3 data by the end of 2026, the company has not committed to a new timeline or sample size for the first look at registration data.